Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics.

Drug discovery Mechanism P2X receptors P2Y receptors Purinergic P2 receptors

Journal

Journal of advanced research
ISSN: 2090-1224
Titre abrégé: J Adv Res
Pays: Egypt
ID NLM: 101546952

Informations de publication

Date de publication:
31 Mar 2024
Historique:
received: 17 01 2024
revised: 03 03 2024
accepted: 29 03 2024
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 2 4 2024
Statut: aheadofprint

Résumé

Purinergic P2 receptors, which can be divided into ionotropic P2X receptors and metabotropic P2Y receptors, mediate cellular signal transduction of purine or pyrimidine nucleoside triphosphates and diphosphate. Based on the wide expression of purinergic P2 receptors in tissues and organs, their significance in homeostatic maintenance, metabolism, nociceptive transmission, and other physiological processes is becoming increasingly evident, suggesting that targeting purinergic P2 receptors to regulate biological functions and signal transmission holds significant promise for disease treatment. This review highlights the detailed mechanisms by which purinergic P2 receptors engage in physiological and pathological progress, as well as providing prospective strategies for discovering clinical drug candidates. The purinergic P2 receptors regulate complex signaling and molecular mechanisms in nervous system, digestive system, immune system and as a result, controlling physical health states and disease progression. There has been a significant rise in research and development focused on purinergic P2 receptors, contributing to an increased number of drug candidates in clinical trials. A few influential pioneers have laid the foundation for advancements in the evaluation, development, and of novel purinergic P2 receptors modulators, including agonists, antagonists, pharmaceutical compositions and combination strategies, despite the different scaffolds of these drug candidates. These advancements hold great potential for improving therapeutic outcomes by specifically targeting purinergic P2 receptors.

Sections du résumé

BACKGROUND BACKGROUND
Purinergic P2 receptors, which can be divided into ionotropic P2X receptors and metabotropic P2Y receptors, mediate cellular signal transduction of purine or pyrimidine nucleoside triphosphates and diphosphate. Based on the wide expression of purinergic P2 receptors in tissues and organs, their significance in homeostatic maintenance, metabolism, nociceptive transmission, and other physiological processes is becoming increasingly evident, suggesting that targeting purinergic P2 receptors to regulate biological functions and signal transmission holds significant promise for disease treatment.
AIM OF REVIEW OBJECTIVE
This review highlights the detailed mechanisms by which purinergic P2 receptors engage in physiological and pathological progress, as well as providing prospective strategies for discovering clinical drug candidates.
KEY SCIENTIFIC CONCEPTS OF REVIEW UNASSIGNED
The purinergic P2 receptors regulate complex signaling and molecular mechanisms in nervous system, digestive system, immune system and as a result, controlling physical health states and disease progression. There has been a significant rise in research and development focused on purinergic P2 receptors, contributing to an increased number of drug candidates in clinical trials. A few influential pioneers have laid the foundation for advancements in the evaluation, development, and of novel purinergic P2 receptors modulators, including agonists, antagonists, pharmaceutical compositions and combination strategies, despite the different scaffolds of these drug candidates. These advancements hold great potential for improving therapeutic outcomes by specifically targeting purinergic P2 receptors.

Identifiants

pubmed: 38565403
pii: S2090-1232(24)00123-1
doi: 10.1016/j.jare.2024.03.027
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Production and hosting by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yanshuo Guo (Y)

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Tianqi Mao (T)

College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.

Yafei Fang (Y)

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Hui Wang (H)

College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.

Jiayue Yu (J)

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Yifan Zhu (Y)

College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.

Shige Shen (S)

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Mengze Zhou (M)

School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Electronic address: zmz@cpu.edu.cn.

Huanqiu Li (H)

College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China. Electronic address: huanqiuli@suda.edu.cn.

Qinghua Hu (Q)

School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: huqh@cpu.edu.cn.

Classifications MeSH